$PLUR News

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

Pluri Commences ~$3.3M Offering Of 2.229M Common Shares At $1.50 Per Share

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

Pluri Unit Cellav Health And Aesthetics Completes Cosmetic Regulatory Registration And Notification In The UK, Supporting Commercial Launch Of Regenativo+

Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%

Pluri Announces Chairman Alejandro Weinstein Has Invested $17M+In PLUR, Including A $1.25M Advance Investment Made In June 2026

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri Announces Completion Of Development And U.S. Cosmetic Product Listings For Two Flagship Regenerative Aesthetic Products, Regenativo+ And Placento+, Clearing Way For U.S. Commercial Launch

Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In

Pluri Insider Ups Holding During Year

Plurilock Announces Payment of Debenture Interest

Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement

Pluri Signs Agreement With Beneficiary Owned By Chairman Alejandro Weinstein For Additional $2.5M Investment In Co.

Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent

Pluri Subsidiary Puri Biotech Secures Patent Covering 3D Immune Cell Expansion Tech

Pluri: Fiscal Q2 Earnings Snapshot

Pluri Q2 EPS $(0.71) Misses $(0.65) Estimate, Sales $198.000K Miss $638.000K Estimate

Pluri showcases cell expansion platform as Resbiomed program advances

Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials